Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 344

1.

Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targets.

Weinberg BA, Xiu J, Lindberg MR, Shields AF, Hwang JJ, Poorman K, Salem ME, Pishvaian MJ, Holcombe RF, Marshall JL, Morse MA.

J Gastrointest Oncol. 2019 Aug;10(4):652-662. doi: 10.21037/jgo.2018.08.18.

2.

Perspectives on Treatment of Metastatic Colorectal Cancer with Immune Checkpoint Inhibitor Therapy.

Morse MA, Hochster H, Benson A.

Oncologist. 2019 Aug 5. pii: theoncologist.2019-0176. doi: 10.1634/theoncologist.2019-0176. [Epub ahead of print] Review.

PMID:
31383813
3.

Impact of synchronized anti-PD-1 with Ad-CEA vaccination on inhibition of colon cancer growth.

Sun Y, Wang S, Yang H, Wu J, Li S, Qiao G, Wang S, Wang X, Zhou X, Osada T, Hobeika A, Morse MA, Ren J, Lyerly HK.

Immunotherapy. 2019 Aug;11(11):953-966. doi: 10.2217/imt-2019-0055. Epub 2019 Jun 13.

PMID:
31192764
4.

Safety of Nivolumab plus Low-Dose Ipilimumab in Previously Treated Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer.

Morse MA, Overman MJ, Hartman L, Khoukaz T, Brutcher E, Lenz HJ, Atasoy A, Shangguan T, Zhao H, El-Rayes B.

Oncologist. 2019 May 30. pii: theoncologist.2019-0129. doi: 10.1634/theoncologist.2019-0129. [Epub ahead of print]

PMID:
31147488
5.

Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study).

Le DT, Picozzi VJ, Ko AH, Wainberg ZA, Kindler H, Wang-Gillam A, Oberstein P, Morse MA, Zeh HJ 3rd, Weekes C, Reid T, Borazanci E, Crocenzi T, LoConte NK, Musher B, Laheru D, Murphy A, Whiting C, Nair N, Enstrom A, Ferber S, Brockstedt DG, Jaffee EM.

Clin Cancer Res. 2019 Sep 15;25(18):5493-5502. doi: 10.1158/1078-0432.CCR-18-2992. Epub 2019 May 24.

PMID:
31126960
6.

Functional CD3+CD8+PD1- T Cell Accumulation and PD-L1 Expression Increases During Tumor Invasion in DCIS of the Breast.

Lv S, Wang S, Qiao G, Wang X, Zhou X, Yan F, Li Y, Wang S, Morse MA, Hobeika A, Ren J, Lyerly HK.

Clin Breast Cancer. 2019 Apr 16. pii: S1526-8209(19)30213-7. doi: 10.1016/j.clbc.2019.04.001. [Epub ahead of print]

PMID:
31101455
7.

Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results.

Sharma P, Siefker-Radtke A, de Braud F, Basso U, Calvo E, Bono P, Morse MA, Ascierto PA, Lopez-Martin J, Brossart P, Rohrberg K, Mellado B, Fischer BS, Meadows-Shropshire S, Abdel Saci, Callahan MK, Rosenberg J.

J Clin Oncol. 2019 Jul 1;37(19):1608-1616. doi: 10.1200/JCO.19.00538. Epub 2019 May 17. Erratum in: J Clin Oncol. 2019 Aug 10;37(23):2094.

PMID:
31100038
8.

Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIMSM registry.

Fishman M, Dutcher JP, Clark JI, Alva A, Miletello GP, Curti B, Agarwal N, Hauke R, Mahoney KM, Moon H, Treisman J, Tykodi SS, Daniels G, Morse MA, Wong MKK, Kaufman H, Gregory N, McDermott DF.

J Immunother Cancer. 2019 Mar 27;7(1):84. doi: 10.1186/s40425-019-0567-3.

9.

Prospective randomized comparative study on rivaroxaban and LMWH for prophylaxis of post-apheresis thrombosis in adoptive T cell immunotherapy cancer patients.

Wang X, Wang S, Morse MA, Jiang N, Zhao Y, Song Y, Zhou L, Huang H, Zhou X, Hobeika A, Ren J, Lyerly HK.

J Thromb Thrombolysis. 2019 May;47(4):505-511. doi: 10.1007/s11239-019-01844-7.

PMID:
30903459
10.

A Phase I-II Study Using Rexin-G Tumor-Targeted Retrovector Encoding a Dominant-Negative Cyclin G1 Inhibitor for Advanced Pancreatic Cancer.

Chawla SP, Bruckner H, Morse MA, Assudani N, Hall FL, Gordon EM.

Mol Ther Oncolytics. 2018 Dec 14;12:56-67. doi: 10.1016/j.omto.2018.12.005. eCollection 2019 Mar 29.

11.

Niclosamide-induced Wnt signaling inhibition in colorectal cancer is mediated by autophagy.

Wang J, Ren XR, Piao H, Zhao S, Osada T, Premont RT, Mook RA Jr, Morse MA, Lyerly HK, Chen W.

Biochem J. 2019 Feb 8;476(3):535-546. doi: 10.1042/BCJ20180385.

PMID:
30635359
12.

Vaccine-Induced Memory CD8+ T Cells Provide Clinical Benefit in HER2 Expressing Breast Cancer: A Mouse to Human Translational Study.

Crosby EJ, Gwin W, Blackwell K, Marcom PK, Chang S, Maecker HT, Broadwater G, Hyslop T, Kim S, Rogatko A, Lubkov V, Snyder JC, Osada T, Hobeika AC, Morse MA, Lyerly HK, Hartman ZC.

Clin Cancer Res. 2019 May 1;25(9):2725-2736. doi: 10.1158/1078-0432.CCR-18-3102. Epub 2019 Jan 11.

PMID:
30635338
13.

Autologous Dendritic Cell-Cytokine Induced Killer Cell Immunotherapy Combined with S-1 Plus Cisplatin in Patients with Advanced Gastric Cancer: A Prospective Study.

Qiao G, Wang X, Zhou L, Zhou X, Song Y, Wang S, Zhao L, Morse MA, Hobeika A, Song J, Yi X, Xia X, Ren J, Lyerly HK.

Clin Cancer Res. 2019 Mar 1;25(5):1494-1504. doi: 10.1158/1078-0432.CCR-18-2360. Epub 2018 Dec 4.

PMID:
30514775
14.

Combination of DC/CIK adoptive T cell immunotherapy with chemotherapy in advanced non-small-cell lung cancer (NSCLC) patients: a prospective patients' preference-based study (PPPS).

Zhao Y, Qiao G, Wang X, Song Y, Zhou X, Jiang N, Zhou L, Huang H, Zhao J, Morse MA, Hobeika A, Ren J, Lyerly HK.

Clin Transl Oncol. 2019 Jun;21(6):721-728. doi: 10.1007/s12094-018-1968-3. Epub 2018 Oct 29.

PMID:
30374838
15.

Impact of Microcystin-LR on Liver Function Varies by Dose and Sex in Mice.

Mrdjen I, Morse MA, Ruch RJ, Knobloch TJ, Choudhary S, Weghorst CM, Lee J.

Toxins (Basel). 2018 Oct 28;10(11). pii: E435. doi: 10.3390/toxins10110435.

16.

The Role of Angiogenesis in Hepatocellular Carcinoma.

Morse MA, Sun W, Kim R, He AR, Abada PB, Mynderse M, Finn RS.

Clin Cancer Res. 2019 Feb 1;25(3):912-920. doi: 10.1158/1078-0432.CCR-18-1254. Epub 2018 Oct 1. Review.

PMID:
30274981
17.

Subacute cutaneous lupus erythematosus and dermatomyositis associated with anti-programmed cell death 1 therapy.

Marano AL, Clarke JM, Morse MA, Shah A, Barrow W, Selim MA, Hall RP 3rd, Cardones AR.

Br J Dermatol. 2019 Sep;181(3):580-583. doi: 10.1111/bjd.17245. Epub 2018 Dec 10.

PMID:
30244487
18.

Where We Stand With Immunotherapy in Colorectal Cancer: Deficient Mismatch Repair, Proficient Mismatch Repair, and Toxicity Management.

Overman MJ, Ernstoff MS, Morse MA.

Am Soc Clin Oncol Educ Book. 2018 May 23;38:239-247. doi: 10.1200/EDBK_200821. Review.

PMID:
30231358
19.

Cell-Free DNA Profiling to Discover Mechanisms of Exceptional Response to Cabozantinib Plus Panitumumab in a Patient With Treatment Refractory Metastatic Colorectal Cancer.

Jia J, Morse MA, Nagy RJ, Lanman RB, Strickler JH.

Front Oncol. 2018 Aug 28;8:305. doi: 10.3389/fonc.2018.00305. eCollection 2018.

20.

Polyfunctional anti-human epidermal growth factor receptor 3 (anti-HER3) antibodies induced by HER3 vaccines have multiple mechanisms of antitumor activity against therapy resistant and triple negative breast cancers.

Osada T, Hartman ZC, Wei J, Lei G, Hobeika AC, Gwin WR, Diniz MA, Spector N, Clay TM, Chen W, Morse MA, Lyerly HK.

Breast Cancer Res. 2018 Aug 9;20(1):90. doi: 10.1186/s13058-018-1023-x.

21.

Comparison of Clinical and Echocardiographic Outcomes After Surgical Redo Mitral Valve Replacement and Transcatheter Mitral Valve-in-Valve Therapy.

Kamioka N, Babaliaros V, Morse MA, Frisoli T, Lerakis S, Iturbe JM, Binongo J, Corrigan F, Yousef A, Gleason P, Wells JA 4th, Caughron H, Dong A, Rodriguez E, Leshnower B, O'Neill W, Paone G, Eng M, Guyton R, Block PC, Greenbaum A.

JACC Cardiovasc Interv. 2018 Jun 25;11(12):1131-1138. doi: 10.1016/j.jcin.2018.03.011.

22.

Predictors of Survival in 211 Patients with Stage IV Pulmonary and Gastroenteropancreatic MIBG-Positive Neuroendocrine Tumors Treated with 131I-MIBG.

Kane A, Thorpe MP, Morse MA, Howard BA, Oldan JD, Zhu J, Wong TZ, Petry NA, Reiman R Jr, Borges-Neto S.

J Nucl Med. 2018 Nov;59(11):1708-1713. doi: 10.2967/jnumed.117.202150. Epub 2018 May 18.

PMID:
29777005
23.

Complimentary mechanisms of dual checkpoint blockade expand unique T-cell repertoires and activate adaptive anti-tumor immunity in triple-negative breast tumors.

Crosby EJ, Wei J, Yang XY, Lei G, Wang T, Liu CX, Agarwal P, Korman AJ, Morse MA, Gouin K, Knott SRV, Lyerly HK, Hartman ZC.

Oncoimmunology. 2018 Jan 19;7(5):e1421891. doi: 10.1080/2162402X.2017.1421891. eCollection 2018.

24.

BET bromodomain inhibitors show anti-papillomavirus activity in vitro and block CRPV wart growth in vivo.

Morse MA, Balogh KK, Brendle SA, Campbell CA, Chen MX, Furze RC, Harada IL, Holyer ID, Kumar U, Lee K, Prinjha RK, Rüdiger M, Seal JT, Taylor S, Witherington J, Christensen ND.

Antiviral Res. 2018 Jun;154:158-165. doi: 10.1016/j.antiviral.2018.03.012. Epub 2018 Apr 11.

25.

The role of external beam radiotherapy in the treatment of hepatocellular cancer.

Chino F, Stephens SJ, Choi SS, Marin D, Kim CY, Morse MA, Godfrey DJ, Czito BG, Willett CG, Palta M.

Cancer. 2018 Sep 1;124(17):3476-3489. doi: 10.1002/cncr.31334. Epub 2018 Apr 12. Review.

26.

A Phase I Trial of the IGF-1R Antibody Ganitumab (AMG 479) in Combination with Everolimus (RAD001) and Panitumumab in Patients with Advanced Cancer.

Vlahovic G, Meadows KL, Hatch AJ, Jia J, Nixon AB, Uronis HE, Morse MA, Selim MA, Crawford J, Riedel RF, Zafar SY, Howard LA, O'Neill M, Meadows JJ, Haley ST, Arrowood CC, Rushing C, Pang H, Hurwitz HI.

Oncologist. 2018 Jul;23(7):782-790. doi: 10.1634/theoncologist.2016-0377. Epub 2018 Mar 23.

27.

Whole Recombinant Saccharomyces cerevisiae Yeast Expressing Ras Mutations as Treatment for Patients With Solid Tumors Bearing Ras Mutations: Results From a Phase 1 Trial.

Cohn A, Morse MA, O'Neil B, Whiting S, Coeshott C, Ferraro J, Bellgrau D, Apelian D, Rodell TC.

J Immunother. 2018 Apr;41(3):141-150. doi: 10.1097/CJI.0000000000000219.

28.

Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer.

Overman MJ, Lonardi S, Wong KYM, Lenz HJ, Gelsomino F, Aglietta M, Morse MA, Van Cutsem E, McDermott R, Hill A, Sawyer MB, Hendlisz A, Neyns B, Svrcek M, Moss RA, Ledeine JM, Cao ZA, Kamble S, Kopetz S, André T.

J Clin Oncol. 2018 Mar 10;36(8):773-779. doi: 10.1200/JCO.2017.76.9901. Epub 2018 Jan 20.

PMID:
29355075
29.

XIAP Regulation by MNK Links MAPK and NFκB Signaling to Determine an Aggressive Breast Cancer Phenotype.

Evans MK, Brown MC, Geradts J, Bao X, Robinson TJ, Jolly MK, Vermeulen PB, Palmer GM, Gromeier M, Levine H, Morse MA, Van Laere SJ, Devi GR.

Cancer Res. 2018 Apr 1;78(7):1726-1738. doi: 10.1158/0008-5472.CAN-17-1667. Epub 2018 Jan 19.

30.

Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIMSM registry.

Curti B, Daniels GA, McDermott DF, Clark JI, Kaufman HL, Logan TF, Singh J, Kaur M, Luna TL, Gregory N, Morse MA, Wong MKK, Dutcher JP.

J Immunother Cancer. 2017 Dec 19;5(1):102. doi: 10.1186/s40425-017-0307-5.

31.

CYP1A1 genetic polymorphism is a promising predictor to improve chemotherapy effects in patients with metastatic breast cancer treated with docetaxel plus thiotepa vs. docetaxel plus capecitabine.

Zhou X, Qiao G, Wang X, Song Q, Morse MA, Hobeika A, Gwin WR, Ren J, Lyerly HK.

Cancer Chemother Pharmacol. 2018 Feb;81(2):365-372. doi: 10.1007/s00280-017-3500-9. Epub 2017 Dec 14.

PMID:
29242966
32.

A Blueprint to Advance Colorectal Cancer Immunotherapies.

Le DT, Hubbard-Lucey VM, Morse MA, Heery CR, Dwyer A, Marsilje TH, Brodsky AN, Chan E, Deming DA, Diaz LA Jr, Fridman WH, Goldberg RM, Hamilton SR, Housseau F, Jaffee EM, Kang SP, Krishnamurthi SS, Lieu CH, Messersmith W, Sears CL, Segal NH, Yang A, Moss RA, Cha E, O'Donnell-Tormey J, Roach N, Davis AQ, McAbee K, Worrall S, Benson AB.

Cancer Immunol Res. 2017 Nov;5(11):942-949. doi: 10.1158/2326-6066.CIR-17-0375. Epub 2017 Oct 16.

33.

In Vivo Detection of HSP90 Identifies Breast Cancers with Aggressive Behavior.

Osada T, Kaneko K, Gwin WR, Morse MA, Hobeika A, Pogue BW, Hartman ZC, Hughes PF, Haystead T, Lyerly HK.

Clin Cancer Res. 2017 Dec 15;23(24):7531-7542. doi: 10.1158/1078-0432.CCR-17-1453. Epub 2017 Oct 9.

34.

Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study.

Overman MJ, McDermott R, Leach JL, Lonardi S, Lenz HJ, Morse MA, Desai J, Hill A, Axelson M, Moss RA, Goldberg MV, Cao ZA, Ledeine JM, Maglinte GA, Kopetz S, André T.

Lancet Oncol. 2017 Sep;18(9):1182-1191. doi: 10.1016/S1470-2045(17)30422-9. Epub 2017 Jul 19. Erratum in: Lancet Oncol. 2017 Sep;18(9):e510.

35.

Vaccination targeting human HER3 alters the phenotype of infiltrating T cells and responses to immune checkpoint inhibition.

Osada T, Morse MA, Hobeika A, Diniz MA, Gwin WR, Hartman Z, Wei J, Guo H, Yang XY, Liu CX, Kaneko K, Broadwater G, Lyerly HK.

Oncoimmunology. 2017 Apr 12;6(6):e1315495. doi: 10.1080/2162402X.2017.1315495. eCollection 2017.

36.

Dendritic Cell/Cytokine-Induced Killer Cell Immunotherapy Combined with S-1 in Patients with Advanced Pancreatic Cancer: A Prospective Study.

Jiang N, Qiao G, Wang X, Morse MA, Gwin WR, Zhou L, Song Y, Zhao Y, Chen F, Zhou X, Huang L, Hobeika A, Yi X, Xia X, Guan Y, Song J, Ren J, Lyerly HK.

Clin Cancer Res. 2017 Sep 1;23(17):5066-5073. doi: 10.1158/1078-0432.CCR-17-0492. Epub 2017 Jun 13.

37.

Adaptive T cell responses induced by oncolytic Herpes Simplex Virus-granulocyte macrophage-colony-stimulating factor therapy expanded by dendritic cell and cytokine-induced killer cell adoptive therapy.

Ren J, Gwin WR, Zhou X, Wang X, Huang H, Jiang N, Zhou L, Agarwal P, Hobeika A, Crosby E, Hartman ZC, Morse MA, H Eng K, Lyerly HK.

Oncoimmunology. 2016 Dec 7;6(4):e1264563. doi: 10.1080/2162402X.2016.1264563. eCollection 2017.

38.

Phase I study of pazopanib plus TH-302 in advanced solid tumors.

Riedel RF, Meadows KL, Lee PH, Morse MA, Uronis HE, Blobe GC, George DJ, Crawford J, Niedzwiecki D, Rushing CN, Arrowood CC, Hurwitz HI.

Cancer Chemother Pharmacol. 2017 Mar;79(3):611-619. doi: 10.1007/s00280-017-3256-2. Epub 2017 Feb 25.

PMID:
28238078
39.

Percutaneous biliary drainage catheter insertion in patients with extensive hepatic metastatic tumor burden.

Langman EL, Suhocki PV, Hurwitz HI, Morse MA, Burbridge RA, Smith TP, Kim CY.

J Gastrointest Oncol. 2016 Dec;7(6):875-881. doi: 10.21037/jgo.2016.06.13.

40.

Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIMSM.

Clark JI, Wong MKK, Kaufman HL, Daniels GA, Morse MA, McDermott DF, Agarwala SS, Lewis LD, Stewart JH, Vaishampayan U, Curti B, Gonzalez R, Lutzky J, Rudraptna V, Cranmer LD, Jeter JM, Hauke RJ, Miletello G, Milhem MM, Amin A, Richart JM, Fishman M, Hallmeyer S, Patel SP, Van Veldhuizen P, Agarwal N, Taback B, Treisman JS, Ernstoff MS, Perritt JC, Hua H, Rao TB, Dutcher JP, Aung S.

Clin Genitourin Cancer. 2017 Feb;15(1):31-41.e4. doi: 10.1016/j.clgc.2016.10.008. Epub 2016 Oct 29.

41.

Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma.

Alva A, Daniels GA, Wong MK, Kaufman HL, Morse MA, McDermott DF, Clark JI, Agarwala SS, Miletello G, Logan TF, Hauke RJ, Curti B, Kirkwood JM, Gonzalez R, Amin A, Fishman M, Agarwal N, Lowder JN, Hua H, Aung S, Dutcher JP.

Cancer Immunol Immunother. 2016 Dec;65(12):1533-1544. Epub 2016 Oct 6.

42.

A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma.

Buchbinder EI, Gunturi A, Perritt J, Dutcher J, Aung S, Kaufman HL, Ernstoff MS, Miletello GP, Curti BD, Daniels GA, Patel SP, Kirkwood JM, Hallmeyer S, Clark JI, Gonzalez R, Richart JM, Lutzky J, Morse MA, Sullivan RJ, McDermott DF.

J Immunother Cancer. 2016 Sep 20;4:52. doi: 10.1186/s40425-016-0155-8. eCollection 2016.

43.

Phase 1 Dose Escalation Study of MEDI-565, a Bispecific T-Cell Engager that Targets Human Carcinoembryonic Antigen, in Patients With Advanced Gastrointestinal Adenocarcinomas.

Pishvaian M, Morse MA, McDevitt J, Norton JD, Ren S, Robbie GJ, Ryan PC, Soukharev S, Bao H, Denlinger CS.

Clin Colorectal Cancer. 2016 Dec;15(4):345-351. doi: 10.1016/j.clcc.2016.07.009. Epub 2016 Aug 4.

PMID:
27591895
44.

A phase 1 dose-escalation study of NEO-102 in patients with refractory colon and pancreatic cancer.

Beg MS, Azad NS, Patel SP, Torrealba J, Mavroukakis S, Beatson MA, Wang XP, Arlen PM, Morse MA.

Cancer Chemother Pharmacol. 2016 Sep;78(3):577-84. doi: 10.1007/s00280-016-3108-5. Epub 2016 Jul 23.

45.

Deficient Mismatch Repair and the Role of Immunotherapy in Metastatic Colorectal Cancer.

Quiroga D, Lyerly HK, Morse MA.

Curr Treat Options Oncol. 2016 Aug;17(8):41. doi: 10.1007/s11864-016-0414-4. Review.

PMID:
27315067
46.

Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial.

Antonia SJ, López-Martin JA, Bendell J, Ott PA, Taylor M, Eder JP, Jäger D, Pietanza MC, Le DT, de Braud F, Morse MA, Ascierto PA, Horn L, Amin A, Pillai RN, Evans J, Chau I, Bono P, Atmaca A, Sharma P, Harbison CT, Lin CS, Christensen O, Calvo E.

Lancet Oncol. 2016 Jul;17(7):883-895. doi: 10.1016/S1470-2045(16)30098-5. Epub 2016 Jun 4. Erratum in: Lancet Oncol. 2016 Jul;17 (7):e270. Erratum in: Lancet Oncol. 2019 Feb;20(2):e70.

PMID:
27269741
47.

A Shot to the Heart.

Zurick AO, Morse MA.

J Nucl Cardiol. 2017 Feb;24(1):325-328. doi: 10.1007/s12350-016-0485-4. Epub 2016 Apr 6. No abstract available.

PMID:
27052810
48.

X-linked inhibitor of apoptosis protein mediates tumor cell resistance to antibody-dependent cellular cytotoxicity.

Evans MK, Sauer SJ, Nath S, Robinson TJ, Morse MA, Devi GR.

Cell Death Dis. 2016 Jan 28;7:e2073. doi: 10.1038/cddis.2015.412.

49.

Discovery of Tetrahydropyrazolopyridine as Sphingosine 1-Phosphate Receptor 3 (S1P3)-Sparing S1P1 Agonists Active at Low Oral Doses.

Demont EH, Bailey JM, Bit RA, Brown JA, Campbell CA, Deeks N, Dowell SJ, Eldred C, Gaskin P, Gray JR, Haynes A, Hirst DJ, Holmes DS, Kumar U, Morse MA, Osborne GJ, Renaux JF, Seal GA, Smethurst CA, Taylor S, Watson R, Willis R, Witherington J.

J Med Chem. 2016 Feb 11;59(3):1003-20. doi: 10.1021/acs.jmedchem.5b01512. Epub 2016 Jan 22.

PMID:
26751273
50.

Ascertainment, classification, and impact of neoplasm detection during prolonged treatment with dual antiplatelet therapy with prasugrel vs. clopidogrel following acute coronary syndrome.

Roe MT, Cyr DD, Eckart D, Schulte PJ, Morse MA, Blackwell KL, Ready NE, Zafar SY, Beaven AW, Strickler JH, Onken JE, Winters KJ, Houterloot L, Zamoryakhin D, Wiviott SD, White HD, Prabhakaran D, Fox KA, Armstrong PW, Ohman EM; TRILOGY ACS Investigators.

Eur Heart J. 2016 Jan 21;37(4):412-22. doi: 10.1093/eurheartj/ehv611. Epub 2015 Dec 5.

Supplemental Content

Loading ...
Support Center